Anavex
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Anavex and other ETFs, options, and stocks.About AVXL
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome.
CEOChristopher U. Missling
CEOChristopher U. Missling
Employees42
Employees42
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2004
Founded2004
Employees42
Employees42
AVXL Key Statistics
Market cap669.22M
Market cap669.22M
Price-Earnings ratio-13.66
Price-Earnings ratio-13.66
Dividend yield—
Dividend yield—
Average volume1.04M
Average volume1.04M
High today$7.80
High today$7.80
Low today$7.62
Low today$7.62
Open price$7.65
Open price$7.65
Volume123.89K
Volume123.89K
52 Week high$14.44
52 Week high$14.44
52 Week low$6.62
52 Week low$6.62
AVXL News
TipRanks 6d
Anavex announces new findings for blarcamesineAnavex (AVXL) Life Sciences announced new findings for blarcamesine, an oral small molecule for the potential treatment of early Alzheimer’s disease. New data d...
Benzinga 6d
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control GroupOn Wednesday, Anavex Life Sciences Corp. (NASDAQ:AVXL) announced new findings for blarcamesine, an oral small molecule for early Alzheimer's disease. AVXL stoc...
People also own
Based on the portfolios of people who own AVXL. This list is generated using Robinhood data, and it’s not a recommendation.